Proteo Biotech AG is a clinical-stage biopharmaceutical company focused on advancing its Elafin-based development products into late-stage development and commercialization. The company focuses on developing therapeutic solutions from its innovative Elafin technology for life-threatening complications of surgeries in oncology and life-threatening diseases like pulmonary arterial hypertension. The targeted indications are rare diseases that are subject to specific orphan drug legislations in the European Union and the United States. Proteo has established a network of globally renowned research institutes, physicians and hospitals. – printed on 2021-06-15 10:54:50